Swiss Drug Maker Novartis To Invest Additional $15 Million In Israel's Gamida Cell Novartis is set to make another investment in Israel-based stem cell therapy developer Gamida Cell. The investment will be used for the development of Gamida's experimental treatment known as NiCord. by Ted Ranosa